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Abstract: 
 
The National Health Service (NHS) has recently been the focus of 
government efforts to retain pharmaceutical research in the UK. Efforts to 
foster new partnerships between health care providers and industry have 
been framed with suggestions that clinical trials can offer ‘patient benefit’ 
within the NHS, cutting across ethical and sociological concerns with the 
possible tension between doing research and offering care. This paper draws 
on ethnographic research to explore the sometimes awkward juxtapositions 
between trial protocols and everyday care, individual health and commercial 
profit, and thus the distribution of value produced through trials. While 
researchers appear to find the distinction between research and care useful, 
at least some of the time, both formal and informal strategies for living with 
this distinction may have the unintended consequence of making research 
appear supplementary to rather than simply different from clinical care.  
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Mutual benefit, added value? Doing research  
in the National Health Service  
 
Clinical trials are increasingly geographically dispersed, as industry locates 
research in countries with lower set up costs and more accessible populations 
than in the major pharmaceutical markets of Western Europe and America 
(Petryna 2009; Rajan 2006). This research is managed by a new set of 
commercial actors, contract research organisations (CROs) (Fisher 2006). Yet 
in the UK, the government has been keen to encourage the continuation and 
expansion of commercial trials within the state-funded National Health Service 
(NHS). Most recently it has sought to develop a national infrastructure for 
‘partnership’ working between industry and NHS providers in the name of 
‘mutual benefit’ (Department of Health(DH)/Association of British 
Pharmaceutical Industries 2008). In this paper I draw on ethnographic data 
from a number of trial sites to explore the local negotiation of some of these 
partnerships and benefits. Adding to a literature that has tended to contrast 
the US and regions such as Eastern Europe, Africa and South America, I 
introduce experiences from the UK, using observations from different trials 
shaped by their location in a reasonably well-funded state (i.e. socialised) 
health care system.  
  
The multiplication of value? 
The idea that the UK government should help commercial companies access 
NHS patients as research subjects can be seen as an extension of the state’s 
longstanding involvement with the fortunes of the pharmaceutical industry 
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(Abraham 2009). Recent research policy asks NHS providers to act almost as 
CROs, bringing together different actors to ensure efficient recruitment for 
trials funded by industry as well as medical charities or the state. Rather than 
promoting this activity purely with reference to the economic benefits to the 
national community, the call to site research studies in the NHS has 
increasingly been justified through an appeal to the ‘benefit’ for patients and 
staff in the combination of research and care, a multiplication of value through 
clinical trials. 
 
This tendency to soften the distinction between research and clinical work can 
be traced through research policy discussions over the last decade. For 
example a report published in 2003 by the Academy of Medical Sciences 
suggested that ‘the major beneficiaries of research and development within 
the NHS will undoubtedly be the patients... It is recognised that patients 
involved in clinical trials benefit from the application of the rigorous protocols 
that are a necessary function of this scientific culture. The same culture also 
improves the performance of health care professionals,’ (Academy of Medical 
Sciences 2003, p18). A report from industry and academia, funded by the 
government to consider ‘bioscience’ as a sector, added to this discussion of 
multiple beneficiaries, calling for  ‘mutually advantageous collaboration 
between the NHS and industry for patient benefit’ (Bioscience Innovation and 
Growth Team 2004, p5). The working group set up to consider ways of 
implementing this team’s recommendations about clinical research, under the 
rubric ‘Research for Patient Benefit,’ argued that ‘[trials] will be of benefit to 
both patients and staff [in the NHS] since they have a common desire to 
 5 
reduce uncertainty about the best existing treatments and to evaluate new 
approaches...’ Furthermore, from the perspective of patients, the authors 
claimed, ‘it is notable that participation in a trial ensures the best possible 
standard of care and an assessment, under carefully supervised 
circumstances, of whether there is a better treatment ready to be introduced,’ 
(Research for Patient Benefit Working Group, 2004, p11). Once again present 
as well as future patients – and staff – were described as receiving something 
of value from the research enterprise.  
 
Such policy language cuts across an assumption in ethical discourse that 
clinical work is distinct from experimental work because of their different aims. 
In this model one is understood to focus on ameliorating individual suffering, 
while the other seeks knowledge for the collective. This distinction has led to 
regulatory frameworks to protect the individual, who must be given information 
about the uncertainties involved in research before making an autonomous 
decision to participate. Procedures for seeking such ‘informed consent’ are 
intended to counter what became known as the therapeutic misconception – 
the belief among research participants that professionals are acting in their 
individual best interest (e.g. Lidz et al 2004). Thus the current NHS application 
for review by a Research Ethics Committee requires that the chief investigator 
of any project should clarify the ‘risks and burdens’ attendant on trial 
participation, and set out how these will be shared with participants in consent 
forms and other documents. Applicants are advised that ‘Recruitment material 
should make few, if any, therapeutic promises, there should be no coercion or 
unacceptable inducement,’ (IRAS 2009, p7). 
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Empirical social science also reveals concerns about the combination of 
research and clinical care. Sociologists have tended to see these as 
producing competing demands on health professionals (Fox 1959, Merton 
1976), and expressed doubts about their ability to manage such conflict, 
particularly if clinicians receive direct payments for recruitment to 
commercially funded studies, as is common in both North and South 
American health care systems (Lakoff 2005; Fisher 2009; Petryna 2009). In 
one recent UK study, staff in a specialist genetics clinic reported other 
concerns relating to the potential distortion of either clinical services if 
research funds were used to fill gaps in normal provision or of scientific 
agendas if research teams become too involved in clinical care (Hallowell et al 
2009). As a result professionals in this study described a number of strategies 
designed to separate research from clinical care including: not passing back 
all information generated in the process of research; raising the question of 
research with patients at different times or in different places from those 
associated with healthcare delivery; or using different staff members to 
coordinate research activities. 
 
Despite such concerns, empirical research also shows that clinical staff in 
research roles frequently believe that participants receive benefit from trials, 
for example through additional monitoring and attention (e.g. Fisher 2006). 
For example, Easter et al (2006) drew on interviews with staff and participants 
to describe ‘the many meanings of care’ within research, including physical 
and emotional support. Taking part in trials may represent a realistic route to 
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access services if provision is limited for particular countries or patient 
populations (Petryna 2009; Timmermans and McKay 2009; Timmermans 
forthcoming). This paper draws on ethnographic data to explore concrete 
experiences of the distribution of research and care in the UK’s National 
Health Service. What purchase is there for the concept of ‘mutual benefit’? 
How far do both formal and informal aspects of trial organisation in the UK 
help clinical staff manage research roles, and what are the implications for 
present patients?  
 
Situating trials in the NHS 
The ethnographic work that informs this paper comes from three trials located 
in and around a single NHS Trust, but testing different interventions. Data 
were collected from participant observation of all three trials and interviews 
with research staff in each setting. My involvement intensified over the period 
of data collection between 2002 and 2009 as my work became more 
collaborative, moving from ‘participation’ in the same spaces and activities as 
(patient) participants, to active engagement with discussions of trial design 
and organisation in conversation with researchers. This period also saw 
changes to the field of clinical trials, as government expressed support for the 
sector through the provision of funding, and more importantly tried to 
streamline bureaucracy. A key example of this was the development of an 
Integrated Research Application Service to standardise procedures for 
applying for approval from individual NHS Trusts and ethics review 
committees (quoted above), alongside templates for agreeing and reporting 
on ‘partnership’ between the NHS and industry (DH/ABPI 2008).  
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Data about the effects of such initiatives on actual trial activity are confused. 
Though the UK’s share of the global clinical trials industry has continued a 
gentle decline, industry continues to spend between £1 and £2 billion on 
clinical trials annually (Kinapse 2008), supplementing lower levels of funding 
from the government or medical charities (estimated at just under £1 billion 
between 2004 and 2006, UK Clinical Trials Collaborative 2006).  The ratio of 
industry to charitable/NHS research seems likely to continue in the order of 
2:1 (DH 2005), but there has also been much recent encouragement for co-
funding arrangements. There is no single register offering a comprehensive 
listing of all trials recruiting in the UK across the period, but a portfolio held by 
the National Institute of Health Research indicates that in 2010/11 more than 
2500 trials were ongoing, and that more than 470,000 patients had been 
recruited in 2009/2010.i The cases considered in this paper can thus offer 
only brief examples from a large, diverse and evolving sectorii: illustrating a 
large ‘commercial’ pharmaceutical trial, a smaller trial of innovative technology 
funded by charitable money, and a trial of organisational interventions being 
researched through co-funding arrangements. Despite these limitations, and 
their diversity, my observations reveal shared strategies, both informal and 
formal, for distributing value, or benefit, through and with clinical trials. 
 
Making space for commercial research 
 
Sometime in autumn 2002: I enter the hospital site on foot from 
the tube station and peer at a map to try to locate the 
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Department of Clinical Pharmacology, where I will meet with my 
contact, a researcher on a major pharmaceutical trial. Finding 
the building, I am admitted after pressing a buzzer labelled with 
the name of the trial, looking like a logo. I follow signs to an 
internal door sporting the same logo and am met by the 
researcher. He takes me into a small room that I think I hear 
him calling ‘the feeding room’. ‘This is where we give people 
breakfast,’ he explains. ‘Some of the tests mean they need to 
come here fasting, but we give them something before they go.’ 
It is warm in the room, and as I take off my coat I make small 
talk. ‘I had forgotten how warm hospitals are!’ ‘Strictly speaking 
this is not a hospital,’ he comments quickly. (Research note, 
undated). 
            
This brief record of my first contact with the world of clinical trials stays with 
me as an example of the mindfulness with which my fellow researchers 
approach their work and its definition. At the time, the clinic is one of 
approximately ten centres gathering data for a major multinational study, 
funded by one of the biggest pharmaceutical companies in the world. Though 
the site looks like a hospital ward to me – curtained bays, a single desk 
staffed by nurses, weighing machine – the investigators clearly distinguish the 
place from therapeutic settings. Commercial funding helps make this spatial 
strategy possible by funding a kind of clinical trials unit formally affiliated to a 
university rather than the hospital. This institutional separation is reflected in 
arrangements for recruitment to the trial and the use of medication within it. 
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Like many other pharmaceutical studies, the trial has recruited from patients 
in primary care. Individual family practices are asked to suggest people who 
might be suitable, who are then invited for screening. No patient can be 
enrolled if his or her general practitioner (GP) does not subsequently think it is 
appropriate. Monitoring and the prescription of trial drugs take place in this 
clinic, though records are sent back to the GP throughout. In addition GPs 
may continue to prescribe whatever additional drugs they think appropriate 
during the course of the trial (which will continue for several years). This 
arrangement appears to reduce conflicts of interest, since formally speaking 
the provision of ongoing care is located in primary practice, while the work of 
research is able to operate on a separate level. The existence of the trials unit 
makes this concrete by providing a space and staff distinct from either the 
family practice or hospital.  
 
Nevertheless, different types of care giving are important in both the formal 
design of the trial and its everyday organisation. There is no suggestion that 
this common condition should go untreated, even given the ongoing 
involvement of GPs, so the protocol includes the prescription of drugs to all 
participants.iii The comparison is thus between two different treatment 
modalities, which are themselves quite complicated. These may well go 
beyond the kinds of medication regimens attempted in general practice, so 
that entry into the trial may appear as a kind of referral for specialist 
intervention, although the regimen is adjusted according to protocol rather 
than staff expertise. This protocol based care is available to all participants.  
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Staff members also behave as if they are offering something of value to 
participants, an impression which is supported by some more subtle aspects 
of the setting. The pills used within the trial are brought and taken from the 
clinic in branded carrier bags. These rattle seductively and I come to 
associate them with the ‘goodie bags’ distributed at children’s parties. One 
member of staff refers to the trial site in these terms as she refills a water 
machine with plastic cups one morning. A participant asks, ‘Having a party 
love?’ She replies, with a smile, ‘It’s always a party here!’ The comment is 
indicative of a particular atmosphere at the trial site, which is frequently 
characterised by lively banter.  
 
In contrast to the US trial site observed by Petryna (2009), who saw 
physicians handing pills through a glass window, visits to this site are 
protracted and in many ways personal occasions, as commercial funding 
gives staff extra time. Thus when participants arrive they are greeted 
cheerfully by name and summoned into curtained cubicles for a detailed 
discussion of how they feel, any side effects or symptoms, and various 
measurements and tests. This ‘personal’ concern manifest in the ward is 
continued with the offer of breakfast before participants leave. In a large well-
appointed kitchen, staff members are able to make tea and coffee, toast 
bread, and supply butter, marmite and jam according to participants’ 
preferences. There is a clear feeling that this is a kind of hospitality, and the 
offer is made repeatedly, almost coaxingly. Participants who refuse are 
teased: ‘Mr Smith doesn’t like our breakfasts!’ 
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Yet though the room where these breakfasts are consumed appears to have a 
domestic air, in contrast to the institutional curtains of the ward, there are 
some features on my first visit that strike an odd note. On the ward, the paper 
folders for each participant appear only in small piles set out for each clinic, 
while the work of data management is kept apart or ‘backstage’ (Goffman 
1959). In contrast the ‘frontstage’ of the breakfast room speaks to a degree of 
tension between the different tasks of the trial, for its tables and chairs are 
used for meetings as well as hospitality. There are files in a bookshelf and 
stacked precariously on the windowsill, and one marked ‘RIPs,’ catches my 
eye, an ominous presence amongst the potted plants. On the longest wall, 
opposite a blue sofa, is a large white board. This board was covered with a 
large sheet, which I connected with the RIP file. The researcher explained that 
the team had been looking at some early, blinded comparisons between the 
two trial arms. The graph under the shrouding sheet showed divergent lines, 
representing the two treatment modalities. The implication was that this 
information had to be covered to allow the regular use of the room.  
 
While the work on the ward contained a clear spatial separation between the 
staged ‘clinical’ encounter and the work of accumulating information, echoing 
the separation between the responsibilities left with GPs and those taken on 
by the trial staff, the breakfast room contained a more uneasy combination. At 
the same time, these facilities and the branding evident on the door and on 
the carrier bags handed out to patients spoke of the resources brought into 
the Trust by the contract with a pharmaceutical company running an 
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international study. My second site looked very different, proceeding by self-
consciously rejecting the commercial route for innovation and celebrating its 
location in the resource-strapped NHS.  
 
Side-stepping the market 
My second example comes from a trial of an innovative therapy entirely 
funded by charities, with support in kind from the hospital trust in which it is 
located. Despite these characteristics, it builds on my first example in 
illustrating both how NHS trials are intended to operate apart from service 
delivery, and how both formal and informal aspects of trial organisation 
complicate any such separation. Though the investigators had long-standing 
relationships with commercial firms in this field they described this trial as 
apart from the market, with reference not only to the source of capital but also 
the abandonment of intellectual property rights in the products of the research 
and the recruitment of NHS patients.  
 
‘Industry, that might have been a route, but I think it became 
clear early on, we weren’t talking about a product… The whole 
purpose of this isn’t to come out with the Nobel prize, but more 
than anything to provide for a desperate group of people, 
which is a group we’ve been steered towards from an ethics 
point of view… Our research philosophy here to some degree 
is the no-option patient, partly because not many people 
consider them. Most of the trials that industry brings here are 
[in] selected patients, where they want their [device] to work. 
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The people we increasingly saw were the ones with no option, 
and it was nice to target that group’ (Interview with clinician 
researcher 31/08/07). 
 
Here the trial was set apart from the production of cultural capital (‘the Nobel 
prize’) for the investigator as well as economic value for industry vested in ‘a 
product’. Though the choice to focus on patients with no further treatment 
options was linked to external advice that it would be easier to get ethical 
approval in this group, the speaker ended with a statement about the 
satisfaction that it gave staff to engage with patients ignored by the market.  
 
As proposed in the reports quoted at the start of this paper, the trial design 
effectively offered ‘protocol based’ treatment to all those enrolled. Yet the 
insistence that this group should be defined by having ‘no further treatment 
options’ had a number of important effects. This focus on people who must be 
formally defined as having no alternatives fed a sense among research staff 
and participants that the intervention constituted a kind of ‘last stop’ treatment. 
As part of consent procedures, participants were asked to confirm that they 
understood that they had no further therapeutic options, in several cases 
raising concerns about their life expectancy that they had not discussed with 
their usual clinicians. This resulted in interaction with other NHS staff receding 
into the background, as potential participants focussed on the chance of 
improvement represented by the trial, and defined their interests as being 
permitted to enrol.  
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The statement in the inclusion criteria that participants must be ‘stable on 
optimal therapy’ also connected the practices of recruitment with ongoing 
care. Though intended to ensure that they really did have no other therapeutic 
options, and that any improvement could be linked to the experimental 
intervention, it had the practical consequence that a fairly thorough 
assessment carried out at an initial screening visit frequently resulted in 
changes to treatment plans before recruitment. Needing a formal definition of 
optimal therapy the research team referred to international guidelines, but 
these did not match the experience of many who attend screening. As a result 
researchers engaged in delicate negotiations with their usual clinicians to 
increase or modify their existing treatment, getting involved in therapeutic 
decisions before enrolment.  
 
Yet as in my first example, and as suggested in the literature, ‘care’ is not just 
a matter of therapeutic intent. A culture of good relationships was celebrated 
among research staff as linked to the location of the trial in the NHS in 
general, and in the hospital where they worked, a tertiary centre with strong 
links to the local community and a loyal staff. There was no special site for the 
activity of research here, and participants were lodged on one of the main 
wards when they visited for the intervention.  
 
One of the trial participants is coming in for the intervention 
today. He will stay about a week. I walk with one of the 
research nurses to check that a bed is ready for him upstairs. 
It is a small Victorian hospital, and the ward is at the front. It 
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has a large picture window, but is otherwise quite dark, 
cramped and a bit shabby. She comments, ‘When people 
come for the intervention sometimes they say things about the 
hospital, because they expect something all shiny and white, 
and you know, this is the NHS! But once they’re here, they get 
to know us. Everyone’s very friendly here, everyone knows 
everybody else and it makes for a good atmosphere’ 
(Fieldnotes April 2006). 
 
Like the pharmaceutical study, this trial was defined as different from 
everyday care because of the ‘good atmosphere’ created between staff and 
patients. With the exception of the two principal investigators (both senior 
physicians) the research team used first names and made a point of 
developing jokey, even affectionate, relationships with participants over the 
time they spent in the hospital. The extra time available for such interaction 
was presented as an advantage of doing nursing work in research rather than 
on the wards. 
 
‘The main thing that surprised me is that I’ve got more patient 
contact than I used to, than I expected’ (Conversation with 
nurse researcher, fieldnotes July 2007).  
 
Researchers were careful not to suggest that such enhanced contact is 
necessarily beneficial for participants, and were often worried about the strain 
on them of the journey to the trial site. But it was unusual to see a need to 
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separate the ‘caring role’ from the pursuit of research. In one exceptional case 
this did appear important because of the risks of the experimental procedure 
(not the benefits accruing from usual care). A participant had been in the 
hospital for several days having tests in preparation for receiving the 
intervention or placebo. His blood chemistry appeared to have been adversely 
affected across the stay in hospital and he might have been further 
endangered by elements of the procedure. In this situation, staff diagnosed a 
potential conflict of interest, between looking out for him as a patient and their 
wish to get an additional subject into the trial by administering the intervention, 
a situation complicated by his wish to go ahead. Rather than refer back to the 
patient’s original doctor, the lead researcher sought a resolution through 
delegation at the trial site, appointing a slightly junior doctor as the clinical 
lead, who would collect information on the participant’s current condition and 
move towards a decision grounded in the therapeutic relationship between 
doctor and patient. As a result, the procedure was cancelled. 
 
Though this was a rare event, the initiative to ‘stage’ or ‘reinvent’ a clinical role 
spoke in some sense to the degree to which care had been handed over from 
the patients’ own doctors during the process of recruitment. Though formally 
the architecture of the NHS had separated the care offered by these doctors 
from the research, its location in a specialist centre, and the use of the 
protocol helped create the idea that participation might confer therapeutic 
benefits distinct from the additional time and engagement with patients, even 
before any effects of the experimental intervention. The conditions for this 
came from an ethical framework that suggested that the most experimental 
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treatments should be tested on people with nothing to lose (and implicitly, 
nothing else to gain), but also gained traction in the shared environment of the 
NHS.  
 
Elaborating services in partnership 
If my second example shows a case of research coming after regular 
therapeutic resources are exhausted, my third appeared to insert additional 
resources into the NHS prior to the offer of treatment. The trial followed the 
drug study described in my first example coming out of researchers’ sense 
that participants did well because of the kinds of enhanced contact described 
above.  
 
‘We built up a lot of trust in the time doing [the big drug trial]. 
Local GPs are very suspicious of big Pharma, and often rightly 
so. But with us they saw that their patients were well 
managed, and that they liked coming to the clinic. We were 
able to spend time with them, and as [their health improved] 
the GPs could see the benefits. So everyone was getting 
something,’ (clinician researcher, fieldnotes, September 2008).  
 
Such narratives echoed policy discourse about the shared benefits accruing 
from clinical studies. Yet the absence of direct commercial funding for large 
drug trials (in the increasingly competitive international environment perhaps) 
informed a new approach. This investigator secured an educational grant from 
two drug companies for a trial of interventions to improve practice in a 
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particular clinical area. Here education and/or decision support systems for 
GPs were the object of the experiment. The study explicitly set the provision 
of training in communication with patients (developed through the experience 
of the more leisurely trial interactions described in my first example) against a 
protocol-based approach to up-titrating or altering medication, implemented 
through electronic case management by researchers making suggestions on 
patient records held in primary care.  
 
The study seemed to offer a concrete example of the multiplication of value 
proposed in recent government policy. Industry provided some funding and 
hoped to benefit from the increased use of the drugs used in the traditional 
pharmaceutical study. General practitioners got advice from specialists on 
treating a common condition, and the primary care trust hoped to meet 
government targets and community needs in that area. Yet this arrangement 
appears to presuppose benefit for the patients of practices enrolled in the 
study. To get agreement for the fact that different practices were to receive 
different types of intervention or none (in the control arm), the research team 
drew on arguments, familiar from the first Medical Research Council trials in 
this country, that in a situation of scarcity, randomisation is a fair way to 
distribute common resources. If the trust could not immediately implement 
improvements across the entire community, then an ethical case could be 
made for implementing them in randomly selected practices as part of a 
controlled comparison. The knowledge produced here served as an additional 
form of value to the improvement in treatment that was assumed to follow 
from either education or protocol or both. 
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This organisational justification for the trial made little mention of any risks.  
Indeed the study was formally defined as ‘service improvement’ and thus 
avoided full ethical review. In addition, both formal and informal accounts 
emphasised that the study did not disturb the therapeutic relationship in 
primary care.  
 
‘We don’t see the patients during this period [of the trial], they’re 
your patients, your relationships, we don’t interfere with that,’ 
[quote from presentation at GP practice.] 
 
Yet the researcher also grounded his recommendations in his specialist 
knowledge. For example in educational sessions he made frequent reference 
to ‘more than 7000 patient years’ of experience (accrued in trials), and a wish 
to pass on ‘tips and tricks’ that worked for him in building relationships with 
trial participants. 
 
Even more strikingly, the research team deflected concerns about the co-
funding arrangements for the trial by presenting themselves as uniquely able 
to manage competing priorities. Their experience on research trials made 
them advocates of additional medication in this field, but they were 
independent of any particular pharmaceutical product or company and where 
possible would recommend a generic not a branded product. However they 
also advocated developing the field against a backdrop of concerns about 
prescribing costs in the NHS. In this sense they developed a narrative about 
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both industry and government interests with the idea that both present and 
future patients need protecting from both sides. Though GPs remained the 
immediate care-providers this carved out a role for the researcher in 
managing the social relations surrounding service change.  
 
Discussion 
The examples used above are only snapshots of the very diverse therapeutic 
and economic landscape of clinical trials in the NHS, which according to 
policy makers is being transformed through efforts to increase the UK’s share 
of pharmaceutical research worldwide. However despite these limitations, my 
examples offer evidence of formal and informal strategies for living with what 
may be awkward juxtapositions between experimental protocols and clinical 
care, individual health and commercial profit.  
 
I started this paper with excerpts from recent policy that proposed a kind of 
multiplication of benefits around NHS research. I also noted that some 
theories in both ethics and sociology appear to signal the dangers of such 
claims, in the name of either the vulnerable participant or the conflicted 
researcher. Interview studies with people who actually carry out research give 
some support to both sides in this debate. For example such workers may 
describe efforts to separate care and research (Hallowell et al 2009) but also 
frequently talk about their belief in the benefits that research participants may 
receive (Easter et al 2006; Fisher 2006). In seeking to build on and extend 
this literature with observations of some of the practices that make up NHS 
trials, I want to draw on work by Mol (2002) that makes multiplicity a topic in 
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its own right.  
 
In her ethnographic study of atherosclerosis Mol proposes that disease itself 
is ‘multiple’. Within a hospital different practices – focussing either on patients 
or different parts of the body (arteries viewed in angiography, amputated 
limbs) – effectively produce different definitions of disease and different 
solutions. This ‘incoherence’ is not a problem in medicine, which unlike 
science does not need to produce ‘universal knowledge’ but is practical in its 
focus. ‘Incompatibilities between objects enacted are no obstacle to 
medicine’s capability to intervene – as long as the incompatible variants of an 
object are separated out... Distributions separate out what might otherwise 
clash,’ (Mol 2002, p114-50). In describing the enactment of atherosclerosis 
through practices, Mol identifies a number of possible forms of distribution, for 
example across the patient’s journey between diagnosis and treatment, or 
across a patient population in which some people receive one treatment and 
others receive different interventions. These distributions are often implicit. 
Yet there may also be attempts at coordination: a form of ‘adding up’ for 
example where either one diagnostic test is given greater importance than 
another, or the accumulation of results triggers an intervention; or ‘calibration,’ 
contained in attempts to make diagnostic tests comparable. I want to propose 
that the different kinds of care furthered in both clinical and research work and 
the possible benefits arising from such activities, are also both distributed and 
coordinated. Building on these observations I consider how far the specific 
boundary between research and care appeared important in the trials I 
studied, even as policy appeared to undermine it, to explore the contribution 
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of different formal and informal attempts at either coordination or distribution, 
and to draw attention to the effects of these attempts for the experience of 
staff and patients.  
 
(i) Maintaining a boundary? 
Current ethical frameworks tend to proceed by formally distinguishing 
research from care, such that research requires additional ethical review, 
institutional permissions and audit. The idea of a boundary between research 
and care also appeared important in more informal descriptions of trial work, 
which tended to stress the ongoing responsibility of the usual caregiver for 
ethical concern with the individual patient. In each case described here, 
potential participants were unlikely to be known to researchers before 
screening, but instead were identified by general practitioners or specialists in 
different parts of the NHS. Sending a patient to be considered for inclusion in 
a trial was not understood as passing over therapeutic responsibility. Indeed, 
the need for these doctors to give their permission for their patients to 
participate in research appeared to give this therapeutic relationship primacy, 
and it was also generally expected to continue alongside the research 
encounters (an arrangement known as partial entrustment, Easter et al 2006), 
or in the case of the third trial to be the only actual contact with patients 
(researchers were explicitly kept out of the consultation room).  
 
Moments and spaces where research and care appeared in conflict were 
uncomfortable, but were relatively rare. Indeed as in other studies, different 
and additional forms of care appeared everywhere in my observations. Such 
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personal attention in the trial setting should perhaps not be assumed to be 
‘surplus’ (c.f. Easter et al 2006), but may be fundamental to researchers’ 
ability to enrol patients and other clinicians in their projects. As noted by 
Timmermans (forthcoming) and Fisher (2009) good relationships with 
participants are critical for recruitment, retention and compliance in both 
commercial and non-commercial trials.  
 
Yet the emphasis on the enhanced ‘atmosphere’ of a research project 
appeared the reverse of an ethical concern with research as a poor substitute 
for care. Instead a further boundary was invoked between the particular risks 
of commercial research, and non-commercial research. Here NHS values 
might be offered as an alternative or counterweight to corporate ones, as in 
the second example where accounts of the features specific to this trial acted 
as ‘interferences’ with ‘the market model’ of development (Mol 1999). But they 
could also be brought to the table in negotiating collaboration with commercial 
interests as in the third example in this paper. As proposed in policy 
discourse, the NHS as a ‘caring context’ brought something valuable to the 
practice of research, just as research was imagined to bring something to the 
NHS, and its existence appeared to bridge a gap between the interests of 
individual patients and the collective goals of research. 
 
(ii) Strategies for distribution or coordination  
To the extent that regulation involves setting out differences and relationships 
between the activities of research and care, one might think of it as an attempt 
at coordination in Mol’s (2002) sense of the term. One way of making such 
 25 
comparisons is by assigning different intentions to different roles within an 
organisation, so that the research role is clearly distinguished from care-
giving, yet this use of intentions, rather than activities, has been criticised as 
confusing for patients and staff (Hallowell et al 2009). In the genetics clinic 
studied by these authors, care and research were often closely intertwined – 
yet as in my case this did not result in staff abandoning the distinction. Instead 
they described informal ways of maintaining a boundary, supplementing the 
regulatory focus on informed consent with practices that look more like 
distribution. As noted in my introduction these included at least three 
strategies: treating information from research as categorically different from 
clinical information, which should be fed back to patients; separating research 
from care in time and space, for example by discussing research in separate 
consultations; or using different personnel to further science or deliver care.  
 
The first strategy, withholding information from research participants, was the 
least common one in the examples presented here. Clearly there is likely to 
be some uneveness in the flows of information between staff, patients and 
study sponsors. In my first example data showing the early outcomes of the 
trial population were hidden, if imperfectly, from participants. Yet participants 
might often be asked to accommodate additional information about their 
condition, for example during regular monitoring visits. In the second the 
formal request for informed consent also embodied a demand for participants 
to absorb prognostic information as part of the trial, information that was at 
least sometimes unwelcome.  
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In contrast all three trials observed used both temporal and spatial distribution 
to divide ‘research’ from ‘therapy’. Therapeutic responsibility was generally 
located in an institution acting as the usual care provider, while research was 
located at a specialist centre, to which potential participants were sent, though 
as we have seen in the third example an extra level of protection was claimed 
from the fact that patients never interacted directly with research staff at all. 
Where patients did attend research sites they encountered professionals 
engaged in activities of screening, enrolling, intervening and monitoring, but 
not formally speaking providing therapy. To the extent that other forms of care 
were important, as noted above, these appeared to be further, and more 
informally, distributed at the local level. For example in the first trial the 
curtained cubicles offered sites for expressions of concern and more clinical 
interaction, away from the management of trial data. This personal concern 
was supplemented by the offer of breakfast as a kind of fringe benefit of 
participation in the commercial trial.  
 
Distribution of activities among staff was also a theme in my data. The sites I 
observed employed staff explicitly defined by their research role, especially 
nurses, though clinicians were more likely to combine roles as a ‘clinical 
investigator’. Yet all staff emphasised their ability to move between research 
and different kinds of care, and were generally unselfconscious about offering 
therapeutic advice in certain encounters, for example before enrolment. In 
other words, staff claimed to manage the combination of roles at a personal 
level in the context of the temporal and spatial distribution of activities. The 
exception to this pattern was the use of a junior member of staff to carry 
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therapeutic responsibility in my second example, where more formal 
coordination was attempted at the research site. The need for this spoke of 
the failure of the spatial and temporal distributions described above. 
 
My data on the everyday work of carrying out trials largely confirm arguments 
about the potential value of informal distribution strategies for managing 
different activities in particular institutions (Hallowell et al 2009), though some 
appeared more useful than others in the examples given here. Yet in 
combination for formal coordinations, such informal strategies may also have 
unintended consequences, particularly if we consider the ways in which 
people think about the potential benefits of trials. 
  
(iii) Making research supplementary 
One might argue that the research teams observed in this research were free 
to engage in their own informal negotiations between scientific investigation 
and care giving because real therapeutic responsibility was located 
elsewhere. Bracketing the therapeutic relationship in this way appeared to 
have an ethical effect, presenting clinical care as safe from the interests of 
pharmaceutical companies, government or indeed individual researchers in 
doing trials, as well as the epistemic effect of increasing the relevance of the 
research against service variation (Will 2007). Yet this separation could also 
appear to make research ‘supplementary’ to the basic provision of care.  
 
This effect was particularly clear in this second trial discussed above, where 
the attempt to enrol patients with no other treatment options meant that they 
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were focussed on the trial as offering at least the chance of improvement, and 
a site for accessing some form of ‘treatment’ (those with untreatable 
conditions become the NHS equivalent of the uninsured). Furthermore, the 
delicacy of negotiations around the designation ‘stable on optimal therapy’ in 
this case meant that participants had good reason to feel that they had been 
offered a second opinion and chance at new treatment through the trial.  
 
Though the use of social and clinical inclusion criteria and informed consent 
procedures are intended to make explicit the potentially greater risks and 
particular agendas of research trials, in situations where recruitment operates 
along the same pathways as referral within the NHS as a whole (primary care 
to secondary care, or one hospital to another) the conditions are created for 
this ‘calibrating’ logic to be confused, and the trial to appear as an offer of 
additional even superior advice and treatment.  
 
The vision of the trial as ‘supplementary’ might be confirmed by the extra time 
and money available in the research setting. Even formal discussions of trials 
might imply that research participation included some additional benefits as a 
kind of quid pro quo for the unknown risks of the experimental intervention, 
and that randomisation was not only a statistical matter, or way of disciplining 
professionals (Marks 2000, Chalmers 2005) but a moral technique for 
distributing potential benefits. Such effects also fitted with staff discussion of 
the interaction they enjoyed with trial participants. An emphasis on this 
contact was also observed not only in the time spent in consultations, but also 
expressions of hospitality. The importance of these practices should perhaps 
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make us cautious about assuming that any benefit to trial participation is 
purely down to the application of a protocol.  
 
Conclusion 
Despite the new language of partnership in clinical research, and a long 
history of alignment between the UK government and commercial interests in 
this sector, health policy is also increasingly concerned with cost containment 
in the NHS. In 2005, a Parliamentary Committee recommended a major 
institutional step to address this perceived contradiction, proposing that the 
then Department for Trade and Industry take responsibility for furthering the 
economic potential of drug companies located in the UK, while the 
Department of Health allowed itself to focus more clearly on the pursuit of 
value (House of Commons Health Committee 2005, p6). Such a separation 
strategy has not been adopted around clinical trials, which have been marked 
by the rhetoric of mutual benefits and multiplying value, and, most strikingly, 
by the suggestion that ‘present patients’ as well as future ones have 
something to gain from participating in research. 
 
Since the publication of the Research for Patient Benefit report, a number of 
academic studies have attempted to test this claim empirically. The most 
recent meta-analysis finds very little effect on outcomes in either direction, i.e. 
little evidence of either benefit or harm (Vist et al 2008), in fact the authors 
claim that this increases the generalisability of trial results across unselected 
populations. Despite this epistemic interest in reducing the distinction between 
research and ordinary care, it remains a key principle in ethical discussion 
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and thus in the regulatory framework for trials. In so far as these are 
documented in protocols and ethical reviews, I have proposed that these 
represent particular attempts at coordination between different activities, but 
ones which more often proceed by ‘adding up’ than by conscious calibration.  
 
Though my observations confirm the importance of different kinds of care-
giving for the researcher, the everyday practices of research also represent 
attempts to distribute and thus distinguish activities to various degrees. Such 
strategies may be important when they draw attention to the uneven 
distribution of value that may surround a particular research project. Yet 
where current frameworks and practices make research appear 
‘supplementary’ to clinical practice there appears some risk of ignoring the 
real impact of the separation between primary care clinicians and researchers 
(who appear to have specialist knowledge). When trials are inserted into 
referral patterns within the NHS, boundary work may not have the desired 
ethical effect of flagging the risks of research, but rather make trial 
participation appear more desirable. More research could be done to 
investigate this tentative proposal in other trials, and other settings. 
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i
 http://www.ukcrn.org.uk/index/clinical/portfolio_new/P_news.html accessed 10
th
 July 2010. 
ii
 The trials described in this paper were not chosen to illuminate questions about the distribution of 
benefits specifically, but rather to investigate the broader organisation and scientific justification for trials 
in very different fields, and to compare apparently ‘routine’ research and research claiming to represent 
methodological innovation. Observations of the first trial took place over a few months during my 
doctoral research, while participant observations and interviews relating to the second and third trials 
took place over two years during postdoctoral work. Fieldnotes quoted in this paper therefore come from 
a number of different periods of observation. Quotes from these fieldnotes are necessarily paraphrased, 
but those from interviews are verbatim from transcripts.  
iii
 See also Timmermans (2010) though placebo trials still dominate the field of US research, as 
discussed in Fisher (2009, p189).  
